

## Selected Oral Agents for Type 2 Diabetes

Before prescribing JANUVIA, please read the Prescribing Information and Medication Guide.

### Insufficient insulin release



### Role of JANUVIA:


- DPP-4 rapidly degrades incretins
- JANUVIA increases and prolongs active incretin levels
- Incretins stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner.

### Hepatic glucose overproduction



DPP-4=dipeptidyl peptidase-4.

### Insulin resistance



## Important Information

JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.

## Selected Important Risk Information

JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.

There have been postmarketing reports of acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiating JANUVIA, observe patients carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA.


A dosage adjustment is recommended in patients with moderate or severe renal insufficiency or with end-stage renal disease requiring hemodialysis or peritoneal dialysis.

When JANUVIA (sitagliptin) tablets were used in combination with a sulfonylurea or insulin, medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea or insulin may be required to reduce the risk of hypoglycemia.

(Selected Important Risk Information continued on next page)

# JANUVIA targets 2 core defects of diabetes in a glucose-dependent manner

## Glucose-dependent mechanism targets 2 core defects: insufficient insulin release and hepatic glucose overproduction



● Glucose ● GLP-1 (glucagon-like peptide-1) ● GIP (glucose-dependent insulinotropic peptide)  
➤ DPP-4 (dipeptidyl peptidase-4) ● JANUVIA

### Selected Important Risk Information (*continued*)

When JANUVIA (sitagliptin) tablets were used in combination with a sulfonylurea or insulin, medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo. Therefore, a lower dose of sulfonylurea or insulin may be required to reduce the risk of hypoglycemia.

There have been postmarketing reports of serious hypersensitivity reactions in patients treated with JANUVIA, such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Onset of these reactions occurred within the first 3 months after initiation of treatment with JANUVIA, with some reports occurring after the first dose. If a hypersensitivity reaction is suspected, discontinue JANUVIA, assess for other potential causes for the event, and institute alternative treatment for diabetes.

In clinical studies, the adverse reactions reported, regardless of investigator assessment of causality, in  $\geq 5\%$  of patients treated with JANUVIA as monotherapy and in combination therapy and more commonly than in patients treated with placebo, were upper respiratory tract infection, nasopharyngitis, and headache.

**Before prescribing JANUVIA, please read the Prescribing Information, available at [Januvia.com/hcp](http://Januvia.com/hcp).**

### References:

1. Glucotrol [package insert]. New York, NY: Pfizer Inc; 2006.
2. Glucophage [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.
3. Actos [package insert]. Osaka, Japan: Takeda Pharmaceutical Company Limited; 2007.



Copyright © 2011 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.  
DIAB-1007926-0000 07/11  
[Januvia.com](http://Januvia.com)